Karuna Therapeutics, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense
Impairment loss of right-of-use assets
Amortization of premiums and accretion of discounts on investment securities
Depreciation and amortization expense
Loss on disposal of assets
Accretion of debt discount (Note 5)
Non-cash interest income
Change in fair value of derivative liability (Note 5)
Non-cash interest income, net (Note 5)
Changes in operating assets and liabilities:
Accrued interest on investment securities
Accounts receivable
Prepaid expenses
Other current assets
Right-of-use assets
Other non-current assets
Accounts payable
Accrued expenses
Other current liabilities
Operating lease liability
Deferred lease obligation
Other non-current liabilities

Net cash used in operating activities
Cash flows from investing activities
Purchases of short-term investments
Sales of short-term investments
Purchases of investment securities
Purchase of short-term investments (certificates of deposit)
Maturities of investment securities
Sales of investment securities
Acquisition of property and equipment
Net cash used in investing activities

Cash flows from financing activities
Proceeds from public offering, net of underwriting discounts and commissions
Proceeds from secondary public offering, net of underwriting discounts and commissions
Payment of secondary public offering costs
Proceeds from initial public offering, net of underwriting discounts and commissions
Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs
Purchase of shares to cover employee payroll tax withholdings on stock issued under benefit plans
Proceeds from exercise of stock options
Proceeds from issuance of convertible notes
Proceeds from exercise of warrant
Net cash provided by financing activities

Net increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Supplemental disclosures of cash flows information
Lease liabilities arising from obtaining right-of-use assets
Conversion of redeemable convertible preferred stock into common stock
Conversion of convertible notes, accrued interest and discount upon conversion to preferred stock
Purchases of property and equipment included in accounts payable and accrued expenses

Comments